WARNER-LAMBERT LIPITOR NEWS RELEASE DRAWS FDA OBJECTION DUE TO HEAD-TO-HEAD COMPARISONS AND REFERENCE TO MORBIDITY/MORTALITY FINDINGS OF OTHER STATINS
Executive Summary
A Warner-Lambert press release announcing FDA approval of Lipitor (atorvastatin) and referring to the results of other companies' large-scale statin trials is "misleading," FDA's Division of Drug Marketing, Advertising & Communications declared in a notice-of-violation letter to the company.